Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$63.85 USD
-0.03 (-0.05%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $63.89 +0.04 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Price, Consensus and EPS Surprise
GILD 63.85 -0.03(-0.05%)
Will GILD be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for GILD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GILD
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
J&J (JNJ) Seeks Expanded Use of HIV Drug in US and Europe
GILD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
The Zacks Analyst Blog Highlights NextEra Energy, BP, Gilead Sciences, Hamilton Beach and FONAR
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
Other News for GILD
Gilead reports positive data from trial on severe-form hepatitis drug
FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward
Goldman cuts 2seventy bio to neutral, cites competition concerns
Analysts Are Bullish on These Healthcare Stocks: Option Care Health (OPCH), Gilead Sciences (GILD)
Analysts Offer Insights on Healthcare Companies: Biofrontera (BFRI), Gilead Sciences (GILD) and Ventyx Biosciences (VTYX)